Tag Archives: biotechnology news

Myriad Settles – Questions Remain

Posted on January 27, 2015 by Warren Woessner

Yesterday, Myriad announced it has settled the BRCA assay litigations that had been ongoing—and not going well– with Pathway Genomics, Invitae and Gene by Gene (and I assume….Ambry and Labcorp). Although I was just about at the brink of shouting … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Canadian Hospital To Travel The Long And Winding Road Of “Gene Patenting”

Posted on November 3, 2014 by Warren Woessner

Arguing that human DNA is a natural product, the Children’s Hospital of Eastern Ontario (CHEO) has filed suit in Federal Court to invalidate patents claiming human DNA or diagnostic methods that use it. It has been reported that CHEO was … Continue reading →

Posted in Canadian Practice | Tagged , , , , , , , , , , | Leave a comment

101 Rejections Under the Guidelines: Mayo and Myriad “Go Viral”

Posted on September 4, 2014 by Warren Woessner

This is a guest post from Hans Sauer, Deputy General Counsel, Intellectual Property for BIO. “Recently, I set out to find real-world examples of recent rejections under the USPTO Guidance, to do my own sampling rather than rely on reported … Continue reading →

Posted in Claim Interpretation | Tagged , , , , , , , , , , , , | 1 Comment

BIO IP & Diagnostics Symposium

Posted on September 2, 2014 by Warren Woessner

Warren Woessner will be moderating a panel on university-industry (from start-ups to big pharma) partnering in the area of companion diagnostics and personalized medicine at the BIO IP and Diagnostics Symposium, September 26th at the Alexandria Hilton. Since the first two … Continue reading →

Posted in Conferences and Classes | Tagged , , , , , | Leave a comment